Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy

Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?

(2011) Marissa V. Powers et al.   CELL CYCLE

Differential Proteomics Identification of HSP90 as Potential Serum Biomarker in Hepatocellular Carcinoma by Two-dimensional Electrophoresis and Mass Spectrometry

(2010) Yiyi Sun et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells

(2010) Boris Shor et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The 90-kDa Heat Shock Protein Hsp90 Protects Tubulin against Thermal Denaturation

(2010) Felix Weis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting HSP90 for cancer therapy

(2009) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

The unfolded protein response during prostate cancer development

(2009) Alex Yick-Lun So et al.   CANCER AND METASTASIS REVIEWS

Novel Hsp90 partners discovered using complementary proteomic approaches

(2009) Pavel A. Tsaytler et al.   CELL STRESS & CHAPERONES

17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside

(2009) Saad Usmani et al.   CURRENT MOLECULAR MEDICINE

Pharmacological Targeting of the Hsp70 Chaperone

(2009) Srikanth Patury et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Bridging the gap: From protein misfolding to protein misfolding diseases

(2009) Leila M. Luheshi et al.   FEBS LETTERS

To fold or not to fold: modulation and consequences of Hsp90 inhibition

(2009) Laura B Peterson et al.   Future Medicinal Chemistry

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines

(2009) Jennifer K. McCleese et al.   INTERNATIONAL JOURNAL OF CANCER

The Cell Line Secretome, a Suitable Tool for Investigating Proteins Releasedin Vivoby Tumors: Application to the Study of p53-Modulated Proteins Secreted in Lung Cancer Cells

(2009) Jérôme Chenau et al.   JOURNAL OF PROTEOME RESEARCH

A Proteomic Investigation of Ligand-dependent HSP90 Complexes Reveals CHORDC1 as a Novel ADP-dependent HSP90-interacting Protein

(2009) Jacob J. Gano et al.   MOLECULAR & CELLULAR PROTEOMICS

A Small Molecule Inhibitor of Inducible Heat Shock Protein 70

(2009) J. I-Ju Leu et al.   MOLECULAR CELL

The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways

(2009) Masashi Kajiro et al.   NATURE CELL BIOLOGY

The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins

(2009) Günter Kramer et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)

(2009) Patrick Y. Wen et al.   NEURO-ONCOLOGY

The Role of Src in Solid Tumors

(2009) D. L. Wheeler et al.   ONCOLOGIST

Proteomic profiling of heat shock proteins: An emerging molecular approach with direct pathophysiological and clinical implications

(2009) Patrizia Bottoni et al.   Proteomics Clinical Applications

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Structural Biology of the Tumor Suppressor p53

(2008) Andreas C. Joerger et al.   Annual Review of Biochemistry

The Hsp90 molecular chaperone: an open and shut case for treatment

(2008) Laurence H. Pearl et al.   BIOCHEMICAL JOURNAL

Discovery and development of heat shock protein 90 inhibitors

(2008) Tony Taldone et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis

(2008) Marissa V. Powers et al.   CANCER CELL

Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma

(2008) Yoshihisa Fujita et al.   CANCER LETTERS

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

(2008) Tzu-Yin Lin et al.   EXPERIMENTAL HEMATOLOGY

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and application of Hsp90 inhibitors

(2007) D SOLIT   DRUG DISCOVERY TODAY